Bernd has more than 25 years of experience in various management positions in the healthcare and hospital and nephrology markets and is a market expert in PD (peritoneal dialysis) and dialysis in general in Austria and Europe.
1996 he sold his company Infus Medizintechnik Austria GmbH to Baxter. In Baxter, he held various positions, started as Sales Manager Renal, then was responsible for all sales in Austria as a procurator.
After Baxter acquired Gambro in 2011, he worked as Managing Director for Baxter/Gambro Renal Austria where he was the interface to hospitals and medical doctors throughout all of Austria and Germany. He holds roughly 4% including options of Zytoprotec's shares.

Christoph is Professor and Head of the Department for Pediatric Nephrology and Gastroenterology at the Medical University of Vienna and an internationally well-known expert in Peritoneal Dialysis (PD). He has spent his whole career in PD (peritoneal dialysis) with a focus on pediatric PD in the General Hospital of Vienna (AKH).
Christoph started his career with research stays at Yale and UCLA in the USA. His scientific focus is on investigating the "dysfunctional cellular stress response" in clinical and experimental PD models. The international importance of this research approach is documented by numerous top-class publications, competitive research funding and academic prices for him and his team (see below).
To translate cutting-edge scientific knowledge into clinical reality, Zytoprotec, in close cooperation with partners at the Medical University Vienna, is at the forefront of PD research in Europe, with leading positions in European research networks (improvepd.eu).
In 2023 Christoph was designated by leading researchers from eight European nations as Coordinator of the Marie Skłodowska-Curie Actions - Doctoral Networks EUDOPD (HE-MSCA-2023-DN) of the Horizon Europe Programme. Action.
He is Co-founder of Zytoprotec still holding roughly 7% of its shares including options.

Bernd has more than 25 years of experience in venture capital financing for biotech companies. He was General Partner and CFO of TVM Capital, a leading European venture capital firm based out of Munich, Germany, from 1993 to 2010.

Bernd has managed and structured more than 100 financings, acquisitions, IPOs and other transactions – mainly in the biotech space. Since 2010, he is a business angel, coach and board member of various biotech companies in the German speaking countries.
He started working with Zytoprotec in 2014 as a member of the Supervisory Board, became Managing Director at the end of 2015, and moved back into the Supervisory Board at the end of 2022. Bernd holds roughly 4.3% including options of Zytoprotec's shares.

Christian is a lawyer and economist by training. He studied in Austria, the US, Spain, Argentina and Australia. In 1993, Christian co-founded Wolf Theiss Rechtsanwälte, a leading CEE/SEE law firm with offices in Austria (Vienna) and twelve other countries in Central and South-Eastern Europe.
Besides being a long-time partner in Wolf Theiss, he became a startup investor more than fifteen years ago, currently holding stakes in more than ten in European tech companies. In his capacity as a startup investor, Christian co-founded Zytoprotec and has ever since taken a leading role – personally and financially – in developing its business and products. He is the largest single shareholder of Zytoprotec with roughly 18% of the shares including options, and is also a Board Member.

Klaus is a translational biomedical researcher in Vienna. Following the foundation of Zytoprotec, he was appointed Head of a PD-focused research laboratory of the Christian Doppler Research Society and was overseeing all research activities in the development of PDprotec® from preclinical research, via patenting to “first in man”. The CD lab was established as a public-private partnership with Zytoprotec.
A leader in the area of proteomics research in PD, he was Visiting Researcher at Harvard Medical School and a full partner of the IMPROVE PD consortium, a Horizon 2020 project of the EU. Since 2016, he heads the CD Lab MSRPD, a public-private partnership of the Medical University Vienna, the Christian Doppler Research Society and Zytoprotec. The project aims to identify molecular stress signatures as surrogate markers of clinical outcome in PD (peritoneal dialysis), and to identify novel cytoprotective additives and to characterize their molecular mode of action.

Rebecca is Senior PostDoc and Group Leader in the CDL-MSRPD, and Principal Investigator in "IMPROVE-PD" (a European Action funded by the EU Horizon 2020 program). During her PhD studies, she completed a six-month research stay at the Universidad Autónoma de Madrid in Spain and transferred unique experimental models of PD to the CDL-MSRDP. In addition to numerous national and international awards, she received the Stanley Shaldon Young Investigator of the Year Award from the ERA (European Renal Association) in 2019 and is since then a board member of the Young Nephrologists Platform of the ERA.

Alexandra has been working in the pharmaceutical industry for more than 20 years. Since 2020 she is leading the PDprotec® product development for Zytoprotec (Head of CMC), including in particular regulatory affairs, production processes and documentation (SOP).

Arnaud has more than 20 years of experience as an Advanced Process and Development Manager. For almost ten years he worked for Baxter, primarily developing PD delivery and container systems. For  several years he led Baxter's global R&D team for the development of various multi-chamber bag systems.
Arnaud was also responsible for the development of new products and technologies in general, defining future strategy and maintaining the existing portfolio. After leaving Baxter, Arnaud co-founded a consultancy, ArTiBulles, which is advising Zytoprotec in relation to its proprietary multi-chamber PD delivery system since 2020.